• About us
• Contact

Advertisement

Organisation › Details

HiberCell (Group)

HiberCell is the first company exclusively focused on tumor dormancy detection and therapeutics. The company is developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers, with the ultimate goal of preventing cancer relapse and metastasis. *

 

	Start	2019-02-07 established (approx)
	Predecessor	Mount Sinai Health System (New York)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Rigby, Alan (HiberCell 201902 CSO + Co-Founder)
	Person 2	Nowacek, Ari (ARCH Venture Partners 201902 Principal)
	Region	New York, NY
	Country	United States (USA)
	Street	619 West 54th Street 8th Floor
	City	10019 New York, NY
	Tel	+1-212-601-2800
		Address record changed: 2022-09-03
Basic data	Employees	n. a.
		* Document for »About Section«: HiberCell Inc.. (2/7/19). "Press Release: HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics. $60.75M Funding Round Led by ARCH Venture Partners with 6 Dimensions Capital". New York, NY.
		Record changed: 2022-09-03

Advertisement

More documents for HiberCell (Group)

• [1] Stilla Technologies SAS. (6/30/21). "Press Release: Stilla Technologies Strengthens Executive Team with Appointment of Matthew Grow, PhD, to Vice President Global Marketing and Commercial Operations". Boston, MA & Paris....
• [2] HiberCell Inc.. (2/7/19). "Press Release: HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics. $60.75M Funding Round Led by ARCH Venture Partners with 6 Dimensions Capital". New York, NY....
• [3] Genomics Medicine Ireland Ltd.. (11/27/18). "Press Release: $400 Million Investment Programme Positions Ireland for Global Leadership in Genomic Research and Advanced Life Sciences"....
• [4] Oxford Nanopore Technologies Ltd.. (10/18/17). "Press Release: WuXi NextCODE Integrates Oxford Nanopore into the Global Platform for Genomic Data". Shanghai, Cambridge, MA & Reykjavik....
• [5] WuXi NextCode. (9/7/17). "Press Release: WuXi NextCode Completes $240 Million Series B Financing". Shanghai, Cambridge, MA & Reykjavik....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.